Shares in Sirtex Medical have been placed in a trading halt while the company assesses the implications of clinical data relating to gastrointestinal cancer treatments.
The cancer treatment developer says it asked for the halt so it has sufficient time to review soon-to-be-released data relating to two treatment studies at the American Society of Clinical Oncology.
Sirtex, whose shares have dropped more than 50 per cent since August amid accusations the company misled investors with overly optimistic sales forecasts, says it expects the data to be material to its business.
Share
